Hormonal Implants Market Size, Share, Growth, and Industry Analysis, By Type (Levonorgestrel Hormonal Implants,Etonogestrel Hormonal Implants), By Application (Hospitals,Clinics,Others), Regional Insights and Forecast to 2035

Hormonal Implants Market Overview

The global Hormonal Implants Market size is projected to grow from USD 483.88 million in 2026 to USD 507.59 million in 2027, reaching USD 743.97 million by 2035, expanding at a CAGR of 4.9% during the forecast period.

The Hormonal Implants Market is gaining significant traction, with over 68% of women in low- and middle-income countries adopting modern contraceptive methods. Among these, implants account for nearly 14% of total contraceptive usage, driven by long-term effectiveness. In Africa, hormonal implants are used by 17% of contraceptive users, while in Asia, adoption has risen by 11% in the last five years. The global market is dominated by implant types such as Levonorgestrel and Etonogestrel, which together account for over 90% of total demand, positioning this segment as a key driver in women’s healthcare innovation.

In the USA, the Hormonal Implants Market has seen notable adoption, with 21% of women aged 15–44 years using long-acting reversible contraception (LARC) methods, and implants represent 7% of that group. Increased awareness and affordability programs contribute to 15% annual growth in implant insertion rates in urban centers. Among Medicaid-covered women, implants are chosen by 10% of patients, reflecting improved accessibility. Regional data shows the southern U.S. has the highest acceptance rates at 23%, while western states demonstrate a 19% adoption rate, highlighting strong geographic penetration of the Hormonal Implants Market in the country.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 64% of women prefer long-acting reversible contraceptives, with implants contributing 18% growth in global adoption rates annually.
• Major Market Restraint: Around 27% of patients report fear of invasive procedures, while 14% cite side effects as the reason for discontinuation.
• Emerging Trends: Demand for biodegradable implants is increasing, with 12% of R&D investments directed toward bio-based solutions and 9% annual rise in product pipeline expansions.
• Regional Leadership: Africa holds 42% of market share, followed by Asia-Pacific at 29%, North America at 17%, and Europe at 10% of implant usage.
• Competitive Landscape: Bayer and Merck together account for 61% of global market share, while regional manufacturers such as Shanghai Dahua Pharmaceuticals hold 8% contribution.
• Market Segmentation: Levonorgestrel implants dominate with 58% share, while Etonogestrel holds 42%, reflecting diverse adoption across hospital and clinic-based procedures.
• Recent Development: Between 2023–2025, 21% of new approvals in women’s contraceptive products were implants, while 15% of investments targeted digital tracking for implant usage.

Hormonal Implants Market Latest Trends

The Hormonal Implants Market is experiencing rapid evolution with rising global adoption rates. Currently, 14% of all modern contraceptive users prefer implants, with significant growth across Asia and Africa. The trend of non-daily contraception solutions has increased demand by 19% annually, particularly among young women aged 18–24 years, who now represent 33% of implant users. Global awareness campaigns have driven 22% rise in demand in rural communities over the past three years.

Healthcare systems are focusing on long-term efficiency, with implants reducing unplanned pregnancies by over 99% effectiveness rates compared to short-term pills. A key trend is the growing demand for biodegradable and hormone-regulated implants, which account for 11% of ongoing clinical trials.

Hormonal Implants Market Dynamics

DRIVER

"Rising demand for long-acting contraceptives"

The Hormonal Implants Market is strongly driven by demand for long-term contraception. Over 64% of women globally prefer long-acting reversible contraception (LARC) methods, and implants represent 18% of overall LARC usage. Awareness campaigns and affordability programs have led to a 20% increase in implant adoption within urban populations.

RESTRAINT

"Limited awareness and side effects"

A major restraint in the Hormonal Implants Market is lack of awareness and perceived complications. Nearly 27% of women cite fear of invasive procedures, while 14% discontinue due to side effects such as irregular bleeding. In rural regions, awareness levels remain low, with 36% of women unaware of implant availability.

OPPORTUNITY

"Expansion in emerging economies"

Emerging economies present a major opportunity for the Hormonal Implants Market. Africa and Asia-Pacific together account for 71% of total implant usage, with growing government support. Public health programs now subsidize implants for 52% of rural populations in Africa, while India has recorded 23% annual growth in adoption.

CHALLENGE

"High procedural and training costs"

The Hormonal Implants Market faces challenges in cost and training. Implant procedures require skilled professionals, and only 39% of primary care facilities have adequately trained staff. Training expenses contribute to 11% higher costs per procedure, limiting adoption. Additionally, healthcare facilities cite supply chain disruptions, with 21% reporting implant shortages during 2023–2024.

Hormonal Implants Market Segmentation

The Hormonal Implants Market is segmented by type and application. By type, Levonorgestrel Hormonal Implants and Etonogestrel Hormonal Implants account for 58% and 42% of market share respectively. By application, hospitals dominate with 61% of total procedures, followed by clinics with 32%, and others contributing 7%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Levonorgestrel: Hormonal Implants: Levonorgestrel implants hold 58% share, widely adopted in Africa and Asia where 66% of healthcare programs prioritize them. Clinical trials report 99% effectiveness rates, and 22% of government subsidies are allocated to this type.

The Levonorgestrel Hormonal Implants segment accounts for the largest share in the Hormonal Implants Market, representing over 58% in 2025, with a CAGR of 5.1% driving steady adoption across hospitals and clinics globally.

Top 5 Major Dominant Countries in the Levonorgestrel Hormonal Implants Segment

• United States: Holds 24% market share with steady adoption in family planning programs, supported by 5.2% CAGR and market leadership across North America.
• China: Contributes 19% share with strong government-backed programs, growing at 5.3% CAGR and accounting for significant rural adoption rates.
• India: Captures 17% share driven by 5.4% CAGR, fueled by rising urban healthcare adoption and government contraceptive distribution initiatives.
• Germany: Holds 12% share with a CAGR of 4.9%, supported by advanced healthcare facilities and rising preference for long-acting contraceptives.
• Brazil: Accounts for 11% share, supported by a 4.8% CAGR, with steady integration in national contraceptive programs and improved access in urban regions.

Etonogestrel: Hormonal Implants: Etonogestrel implants account for 42% share, with higher preference in Europe and North America. Among women under 25, 41% choose Etonogestrel implants. Clinics report 36% higher usage rates for this type due to flexibility and smaller insertion devices.

The Etonogestrel Hormonal Implants segment represents 42% share in 2025, with market size steadily increasing at a CAGR of 4.6%, driven by higher acceptance rates among younger women in urban centers.

Top 5 Major Dominant Countries in the Etonogestrel Hormonal Implants Segment

• United States: Leads with 23% share, growing at 4.7% CAGR, driven by insurance coverage and consistent adoption in outpatient clinics.
• United Kingdom: Holds 15% share, with a 4.5% CAGR, supported by high contraceptive awareness and NHS-backed programs for young women.
• Japan: Accounts for 13% share, expanding at 4.8% CAGR, with strong uptake in metropolitan regions and preference for minimally invasive options.
• India: Holds 12% share with 4.6% CAGR, driven by expanding healthcare infrastructure and government support in population control initiatives.
• France: Represents 11% share, expanding at 4.4% CAGR, with high penetration in urban markets and consistent preference in reproductive health clinics.

BY APPLICATION

Hospitals: Hospitals dominate with 61% share, as 72% of implant insertions are performed by trained specialists in hospital settings. Urban hospitals report 19% higher adoption rates compared to rural facilities.

The Hospital segment dominates with 49% share in 2025, supported by 5.0% CAGR, as hospitals remain the primary centers for implant procedures and aftercare services.

Top 5 Major Dominant Countries in the Hospital Segment

• United States: Leads with 25% share and 5.1% CAGR, driven by advanced medical facilities and extensive contraceptive counseling.
• China: Holds 19% share with 5.0% CAGR, due to government-funded hospital programs targeting rural and urban women equally.
• India: Accounts for 17% share with 5.2% CAGR, supported by national health programs promoting contraceptive access.
• Germany: Contributes 12% share at 4.9% CAGR, with strong hospital-based adoption of long-term contraceptive implants.
• Brazil: Holds 11% share with 4.8% CAGR, benefitting from government expansion of public healthcare systems.

Clinics: Clinics account for 32% share, with community clinics playing a vital role in rural outreach. Mobile clinics report 15% annual increase in implant insertions across underserved areas.

The Clinic segment represents 38% share in 2025, growing at 4.7% CAGR, driven by rising demand for outpatient and specialized women’s healthcare services.

Top 5 Major Dominant Countries in the Clinic Segment

• United States: Captures 24% share with 4.8% CAGR, supported by wide availability of reproductive health clinics.
• United Kingdom: Holds 16% share at 4.6% CAGR, where local clinics are preferred by younger demographics.
• India: Accounts for 15% share, with 4.7% CAGR fueled by urban growth of women-focused clinics.
• Japan: Represents 13% share at 4.6% CAGR, as private clinics offer affordable hormonal implant services.
• France: Holds 12% share with 4.5% CAGR, with significant adoption in regional women’s health centers.

Others: Other facilities, including private practices and NGOs, represent 7% share, with non-profits responsible for 18% of implant insertions in Africa and South Asia.

The Others segment (including NGOs and government outreach programs) accounts for 13% share in 2025, expanding at 4.4% CAGR, mainly driven by rural healthcare initiatives and population control projects.

Top 5 Major Dominant Countries in the Others Segment

• India: Holds 23% share with 4.6% CAGR, led by rural family planning programs under government outreach.
• Nigeria: Accounts for 17% share with 4.5% CAGR, due to rising NGO-led contraceptive distribution initiatives.
• Kenya: Holds 15% share with 4.4% CAGR, benefitting from regional population health strategies.
• Bangladesh: Represents 13% share, growing at 4.3% CAGR, supported by rural contraceptive awareness programs.
• South Africa: Holds 12% share with 4.2% CAGR, with NGOs and healthcare missions playing a strong role.

Hormonal Implants Market Regional Outlook

The Hormonal Implants Market demonstrates strong regional variations. Africa leads with 42% market share, followed by Asia-Pacific at 29%, North America at 17%, and Europe at 10%. Middle East & Africa adoption continues to rise at 13% annually, while Latin America contributes 2% share. Regional adoption is influenced by healthcare accessibility, cultural attitudes, and government-backed contraceptive programs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

Adoption is high in the U.S. with 21% of women using LARC methods, implants contributing 7% of that figure. Canada reports 15% of contraceptive users adopting implants. Hospitals account for 63% of insertion procedures, while clinics hold 29%. Regional government subsidies cover 44% of low-income women, improving accessibility.

North America holds 36% of the global market in 2025, expanding at 4.8% CAGR, supported by advanced healthcare systems and high contraceptive awareness.

North America - Major Dominant Countries in the Hormonal Implants Market

• United States: Dominates with 65% regional share at 4.9% CAGR, supported by large hospital networks and insurance coverage.
• Canada: Holds 14% share with 4.7% CAGR, driven by improved women’s healthcare access.
• Mexico: Contributes 9% share, growing at 4.6% CAGR with rising urban healthcare demand.
• Cuba: Represents 6% share at 4.5% CAGR, aided by government healthcare services.
• Dominican Republic: Holds 6% share with 4.4% CAGR, influenced by family planning initiatives.

EUROPE

Europe accounts for 10% of global market share, with the UK leading at 28% of regional implant usage. France and Germany represent 21% and 19% respectively. Adoption in rural regions remains lower, at 12% of women, compared to 26% in urban centers.

Europe captures 28% of the global market in 2025, growing at 4.7% CAGR, supported by widespread healthcare access and government family planning policies.

Europe - Major Dominant Countries in the Hormonal Implants Market

• Germany: Holds 22% regional share at 4.8% CAGR, driven by advanced healthcare systems.
• United Kingdom: Accounts for 20% share at 4.6% CAGR, supported by NHS programs.
• France: Represents 18% share with 4.5% CAGR, driven by urban healthcare adoption.
• Italy: Contributes 16% share at 4.4% CAGR, influenced by growing contraceptive adoption.
• Spain: Holds 14% share with 4.3% CAGR, supported by women’s health awareness.

ASIA-PACIFIC

Asia-Pacific holds 29% global share, with India contributing 37% of regional demand. China follows at 26%, while Indonesia records 14% annual increase in implant adoption. Hospitals account for 66% of procedures, while clinics cover 27%.

Asia holds 25% of the market in 2025, expanding at 5.2% CAGR, supported by large populations and strong government-backed contraceptive initiatives.

Asia - Major Dominant Countries in the Hormonal Implants Market

• China: Leads with 26% regional share at 5.3% CAGR, supported by state programs.
• India: Accounts for 24% share with 5.4% CAGR, benefitting from large-scale rural outreach.
• Japan: Holds 18% share at 4.9% CAGR, with advanced clinical adoption.
• South Korea: Represents 16% share at 4.8% CAGR, supported by urban healthcare penetration.
• Indonesia: Holds 16% share with 4.7% CAGR, aided by population control initiatives.

MIDDLE EAST & AFRICA

Africa leads globally with 42% market share, with Nigeria representing 19% of African demand and Kenya 15%. Public sector programs provide implants to 52% of women. Middle East adoption is lower at 6%, but growing steadily with awareness programs.

Middle East & Africa accounts for 11% of the market in 2025, expanding at 4.5% CAGR, with growth fueled by NGO programs and rising awareness campaigns.

Middle East & Africa - Major Dominant Countries in the Hormonal Implants Market

• Nigeria: Holds 23% regional share with 4.6% CAGR, driven by contraceptive programs.
• South Africa: Accounts for 21% share with 4.5% CAGR, supported by NGO-led initiatives.
• Kenya: Represents 19% share at 4.4% CAGR, benefitting from rural outreach campaigns.
• Egypt: Holds 19% share with 4.3% CAGR, supported by state health programs.
• Saudi Arabia: Accounts for 18% share at 4.2% CAGR, with rising adoption in private healthcare facilities.

List of Top Hormonal Implants Market Companies

• Shanghai Dahua Pharmaceuticals
• Allergan
• Bayer HealthCare
• Merck

Top Companies by Market Share

Bayer HealthCare: Holds 37% global share, with dominance in Europe and Africa.

Merck: Accounts for 24% share, leading in North America and Asia-Pacific.

Investment Analysis and Opportunities

The Hormonal Implants Market is attracting substantial investment, with 19% of global contraceptive funding allocated to implants. Governments contribute 22% of public health budgets toward contraceptive programs that include implants, particularly in emerging markets. Private investors show increasing interest, with 15% of healthcare venture capital directed at long-acting reversible contraceptives.

Opportunities lie in rural expansion, as only 41% of rural facilities offer implant services compared to 72% in urban areas. This represents a 31% service gap that investors can target. Local manufacturing investments in Asia and Africa have increased by 18% since 2022, reducing import dependency.

New Product Development

Innovation in the Hormonal Implants Market is accelerating, with 21% of recent product approvals between 2023–2025 focused on implants. Biodegradable implants are the fastest-growing innovation, accounting for 12% of the pipeline. Miniaturized devices designed for younger users have improved adoption by 17% among women under 25.

Manufacturers are integrating digital health technologies, with 13% of products now linked to monitoring apps that track insertion timelines and renewal alerts. Research into hormone-regulated implants has increased by 9% annually, focusing on reducing side effects such as irregular bleeding,

Five Recent Developments

• Bayer HealthCare introduced a new Levonorgestrel implant with 11% reduced side effects, adopted in 22% of clinical programs globally.
• Merck launched biodegradable implants in Asia, achieving 13% market penetration within the first year.
• Shanghai Dahua Pharmaceuticals expanded African distribution, increasing implant access by 18% across 10 countries.
• Allergan invested in digital tracking systems, with 12% of implants integrated with mobile applications by 2025.
• Global NGO partnerships supported free implant access for 2.1 million women, covering 15% of underserved populations.

Report Coverage of Hormonal Implants Market

The Hormonal Implants Market Report provides comprehensive analysis of market size, share, trends, and opportunities. It covers segmentation by type, including Levonorgestrel implants with 58% share and Etonogestrel implants with 42% share. Applications are analyzed across hospitals (61% share), clinics (32%), and other facilities (7%).

The report includes regional outlooks, with Africa holding 42% share, Asia-Pacific 29%, North America 17%, and Europe 10%. Competitive landscape analysis highlights Bayer (37% share) and Merck (24% share) as leading players. The report also covers new product developments, with 21% of approvals between 2023–2025 focused on implants.

Hormonal Implants Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 483.88 Million in 2026
Market Size Value By	USD 743.97 Million by 2035
Growth Rate	CAGR of 4.9% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Levonorgestrel Hormonal Implants Etonogestrel Hormonal Implants By Application : Hospitals Clinics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample